OncoMatch/Clinical Trials/NCT05192122
Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
Is NCT05192122 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies non-drug interventions for multiple myeloma.
A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Disease stage
Required: Stage R-ISS I, R-ISS II, R-ISS III (Revised International Staging System (R-ISS))
Revised International Staging System (R-ISS) I,2 or 3
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: maintenance therapy after ASCT — post-ASCT
Received at least 2 years of post ASCT maintenance (patients may have received any number of prior lines of therapy).
Cannot have received: allogeneic hematopoietic cell transplant
Prior allogeneic hematopoietic cell transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Illinois Cancer Center · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05192122 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic cell transplant disqualifies patients from enrollment.
What disease stage is eligible?
Stage R-ISS I or R-ISS II or R-ISS III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages